Both endogenous type I IFNs, which are derived from immune and tumor cells, and exogenous type I IFNs, which are produced by recombinant technology, trigger signaling cascades by interacting with their cognate transmembrane receptor, the IFN-α/β receptor 1 (IFNAR1)–IFNAR2 heterodimer [8]. This evidence concerns the gene IFNAR1 and neoplasm.